VNDA Earnings & Financial Statements
Vanda Pharmaceuticals Inc.
$4.22
-$0.08(-1.86%)
37
Overall
60
Value
18
Tech
34
Quality
Market Cap
$259.99M
Volume
1.02M
52W Range
$4.27 - $9.94
Target Price
$11.75
VNDA earnings and financial statements: Vanda Pharmaceuticals Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
VNDA Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $216.10M | $198.77M | $192.64M | $254.38M | $268.68M |
| Cost of revenue | $13.04M | $11.31M | $14.80M | $24.28M | $25.63M |
| Operating income | -$151.17M | -$40.66M | -$13.95M | $6.33M | $42.16M |
| EBITDA | -$130.54M | -$14.75M | $9.33M | $14.02M | $45.01M |
| Net income | -$220.47M | -$18.90M | $2.51M | $6.28M | $33.15M |
| EPS (diluted) | $-3.74 | $-0.33 | $0.04 | $0.11 | $0.58 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $488.95M | $656.20M | $648.44M | $634.25M | $593.79M |
| Total liabilities | $161.76M | $117.66M | $103.53M | $107.05M | $88.86M |
| Shareholders’ equity | $327.19M | $538.55M | $544.91M | $527.20M | $504.93M |
| Cash and equivalents | $84.85M | $102.32M | $135.82M | $135.03M | $52.07M |
| Long-term debt | $7.07M | $8.09M | $7.01M | $8.81M | $10.05M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$109.44M | -$15.76M | $12.80M | $31.98M | $64.21M |
| Capital expenditure | -$998.0K | -$490.0K | -$383.0K | -$679.0K | -$552.0K |
| Free cash flow | -$110.44M | -$16.25M | $12.42M | $31.30M | $63.66M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | VNDA | $4.22 | -1.9% | 1.02M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Vanda Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW